MedscapeNovember 9, 2026Regulatory
FDA Requires GLP-1 Labels to Add Rare Eye Condition Risk
Reported by Medscape. Read the original →
What the story says
The FDA has mandated that labels for GLP-1 medications include information about the risk of a rare eye condition.
Summarised by a model from Medscape's headline and its own description of the story. We did not read the article, and this is not our reporting — the link above is.
On file here
Every number below is counted from this library's own approved studies — the ones with a page you can open and check. Counts move as papers are filed.
GLP-1 and incretin therapiesclass
14 compounds tracked · 373 studies on file · 163 in humans
What the headline doesn't tell you
- This story is about a class — GLP-1 and incretin therapies — rather than one compound. We track 14 compounds in it, holding 373 studies between them, 163 in humans.
Counted, not written: each line is a sentence filled in from the study counts above. None of it is a judgement about the story or the compound.